New CEO for Idenix

Xconomy Boston — 

Cambridge, MA-based Idenix Pharmaceuticals (NASDAQ: IDIX), an antiviral drug developer, announced today that it has promoted Ronald Renaud, Jr. to the position of president and chief executive. Renaud, who previously served as Idenix’s CFO and treasurer and most recently its chief business officer, will also take a seat on the company’s board of directors. He replaces former Idenix president, CEO, chairman, and board member Jean-Pierre Sommadossi, who resigned “in order to pursue other interests in the biotechnology field,” according to the company announcement. Idenix’s drug pipeline includes two treatments for hepatitis C, which the FDA recently put on clinical hold, due to elevated liver toxicity in some patients who received both drugs.